Journal article
Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
Rheumatology and therapy, v 1(1), pp 21-30
01 Dec 2014
PMID: 27747760
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Introduction: The aim of this study was to compare the response between subsequent use of anti-tumor necrosis factor a (anti-TNF) agents and biologic disease-modifying anti-rheumatic drugs (bDMARD) with other mechanism of action (MOA) in rheumatoid arthritis (RA) patients with history of anti-TNF treatment as their first bDMARD.
Methods: A retrospective chart review was conducted at eight community-based rheumatology practices in the United States in 2012. Routine Assessment of Patient Index Data 3 (RAPID3) response was measured by comparing baseline and 6-month scores. Poor response was defined as decrease <1.8 points, follow-up score >12, or treatment discontinuation before 6 months. Percentages of patients with good and good or moderate RAPID3 response were compared for second and third biologics. Multivariate models controlled for potential confounders.
Results: Of 176 patients whose charts were abstracted, 122 (69.3%) received another antiTNF agent after they discontinued their first anti-TNF. RAPID3 scores were available for 160 patients. A patient receiving a second bDMARD with another MOA had a higher good or moderate response than a patient receiving anti-TNF (53.5 vs. 30.7%, p = 0.01). In the multivariate models, treatment with another MOA was more likely to produce a good RAPID3 response [odds ratio (OR), 2.42; 95% confidence interval (CI), 1.05-5.58] or a good or moderate response (OR, 2.21; 95% CI, 1.23-3.97) than treatment with an anti-TNF.
Conclusion: In patients who have discontinued anti-TNF agents as their first bDMARD, RAPID3 response rates are better for those receiving agents with a different MOA rather than another anti-TNF. Physicians should consider using a bDMARD with a different MOA as the next bDMARD for RA patients whose anti-TNF agent has failed.
Metrics
Details
- Title
- Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
- Creators
- Martin J. Bergman - Taylor Hosp, Ridley Pk, PA 19078 USAEric P. Elkin - Pinnacle Clinical ResearchSarika Ogale - GenentechTripthi Kamath - GenentechMax I. Hamburger - Rheumatology Consultants
- Publication Details
- Rheumatology and therapy, v 1(1), pp 21-30
- Publisher
- Springer Nature
- Number of pages
- 10
- Grant note
- Genentech, Inc., South San Francisco, California, United States Genentech, Inc.; Roche Holding; Genentech
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:000218462100002
- Scopus ID
- 2-s2.0-85017483032
- Other Identifier
- 991021916797004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Rheumatology